Creatine vs Peptides for Recovery: Where the Evidence Stands
One is among the most-studied supplements ever; the others mostly aren't. The contrast is instructive.
Put creatine next to the recovery peptides and the comparison is almost unfair, but it is exactly that imbalance that makes it worth drawing out. The two sit at opposite ends of the evidence spectrum, and seeing them side by side is one of the clearest ways to understand what “evidence-backed” actually means in practice.
Creatine: the boringly well-studied case
Creatine monohydrate is among the most extensively researched sports supplements in existence. The 2017 International Society of Sports Nutrition (ISSN) position stand calls it “the most effective ergogenic nutritional supplement currently available” for high-intensity exercise capacity and lean body mass. Its recovery contribution is partly indirect and partly direct: the position stand notes evidence that creatine can reduce muscle-enzyme efflux and inflammatory markers after intense exercise and help athletes tolerate higher training volumes.
Its safety profile is also well characterized. The ISSN found “no compelling scientific evidence” that short- or long-term creatine use — at up to 30 g/day for as long as five years — harms otherwise healthy people. Typical dosing is a 0.3 g/kg/day load for 5–7 days, then 3–5 g/day maintenance.
Creatine is not exciting, and that is the point. Its case rests on a mountain of human data, consistent effects, and a documented safety record at up to 30 g/day for five years. Very few recovery aids can say the same.
The recovery peptides: a different evidence world
The peptides marketed for recovery, including compounds like BPC-157 and TB-500, occupy almost the opposite position. Much of the enthusiasm rests on animal studies, mechanistic plausibility, and anecdote rather than controlled human trials. A 2025 systematic review of BPC-157 in orthopaedic sports medicine, for instance, screened 544 articles and found just one human clinical study; the rest were preclinical.
Where they actually stand
- Human trials. Sparse to nonexistent for most of these compounds at the doses and uses people are interested in.
- Mechanism. Often genuinely interesting in cell and animal models, which is why the interest exists — but mechanism is not proof of benefit in people.
- Safety. Largely uncharacterized in humans over time, a meaningful unknown rather than a clean bill of health.
- Regulatory status. Not FDA-approved for these uses; BPC-157 was placed in the FDA’s Category 2 (significant safety risks) for compounding in 2023, and product quality in the unregulated market is a real concern.
This is not to say nothing is there. It is to say the evidence has not been gathered, and absence of evidence here is genuinely absence, not a verdict either way.
The instructive contrast
The useful lesson is methodological. Two interventions can both have a plausible story for helping recovery, and yet sit worlds apart in how much we actually know. Creatine earned its standing through repeated, boring, controlled human study. The recovery peptides have a compelling narrative and a thin evidentiary base. A reasonable person weighting risk and proof will treat them very differently.
The takeaway
If the goal is recovery support with the strongest evidence and best-understood safety, creatine is the obvious, unglamorous answer. The recovery peptides may eventually prove useful, but right now they are a bet on mechanism and anecdote, with unknown long-term safety and uneven product quality. The honest bottom line: choose the boring, well-studied option, and treat the peptides as unproven until human trials say otherwise.